Relapsed and Refractory CD5-Expressing T Cell Lymphomas Pipeline

DelveInsight’s, “Relapsed and Refractory CD5-Expressing T Cell Lymphomas - Pipeline Insight, 2025,” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Relapsed and Refractory CD5-Expressing T Cell Lymphomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Understanding

Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Overview

Relapsed and Refractory CD5-Expressing T Cell Lymphomas refers to lymphoma that reappears or grows again after a period of remission or the lymphoma that does not respond to available therapy treatment (meaning that the cancer cells continue to grow). There is no consensus exists on the best therapeutic strategy for relapsed/refractory Peripheral T-Cell Lymphoma (PTCL). CD5 is one of the most common surface markers of malignant T cells, expressed in around 80% of TALLs (T cell acute lymphoblastic leukemia) and T‐cell lymphomas. CD5 as a receptor regulates T‐cell development and function, acting as a negative regulator of TCR‐CD3 signaling. CD5+ T cell lymphomas are a subset of lymphomas that are positive for the surface protein CD5. CD5 is a T cell, B1-a cell, and B-CLL receptor first described over 30 years ago that has been used as surface marker to identify both human and murine cell populations. CD5 is a potentially good target for a T‐cell based CAR therapy.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed and Refractory CD5-Expressing T Cell Lymphomas R&D. The therapies under development are focused on novel approaches for Relapsed and Refractory CD5-Expressing T Cell Lymphomas.

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Recent Developments

• In February 2025, MB-105, a first-in-class CD5-targeted chimeric antigen receptor T-cell therapy, received orphan drug designation for the treatment of relapsed/refractory CD5-positive T-cell lymphoma. In a Phase 1 study (NCT03081910), MB-105 showed a promising overall response rate in patients with T-cell lymphoma and T-cell acute lymphoblastic leukemia.

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Emerging Drugs Chapters

This segment of the Relapsed and Refractory CD5-Expressing T Cell Lymphomas report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Emerging Drugs

 

Anti-CD5 CAR T-cell therapy: iCell Gene Therapeutics

Anti-CD5 CAR T cells are transduced cells in a lentiviral vector to express CD5 chimeric receptor domain on T cells. CAR engineered cells express a single-chain variable fragments (ScFvs) which target CD5 on T cell malignancies. In this engineered cells, the scFV (single-chain variable fragment) nucleotide sequence of anti-CD5 was subcloned into a CAR lentiviral vector. The USFDA has granted Orphan Drug Designation to Anti-CD5 CAR T cells for Peripheral T-cell Lymphoma.

 

MT-101: Myeloid Therapeutics

MT-101 is a potential treatment of Relapsed and Refractory CD5-Expressing T Cell Lymphomas. Refractory PTCL is a lethal disease with limited treatment options that until now has not benefited from innovations in cell therapy. In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity.

Further product details are provided in the report……..

Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Therapeutic Assessment

This segment of the report provides insights about the different Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Relapsed and Refractory CD5-Expressing T Cell Lymphomas

There are approx. 2+ key companies which are developing the Relapsed and Refractory CD5-Expressing T Cell Lymphomas. The companies which have their Relapsed and Refractory CD5-Expressing T Cell Lymphomas drug candidates in the most advanced stage, i.e. Phase I include, iCell Gene Therapeutics.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Relapsed and Refractory CD5-Expressing T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsed and Refractory CD5-Expressing T Cell Lymphomas: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs.

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Report Insights

• Relapsed and Refractory CD5-Expressing T Cell Lymphomas Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Relapsed and Refractory CD5-Expressing T Cell Lymphomas Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs?
• How many Relapsed and Refractory CD5-Expressing T Cell Lymphomas drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Relapsed and Refractory CD5-Expressing T Cell Lymphomas?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsed and Refractory CD5-Expressing T Cell Lymphomas therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsed and Refractory CD5-Expressing T Cell Lymphomas and their status?
• What are the key designations that have been granted to the emerging drugs?